The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 01, 2020
Filed:
Mar. 09, 2017
Applicant:
Merck Patent Gmbh, Darmstadt, DE;
Inventors:
Horacio G. Nastri, Needham, MA (US);
Christel Iffland, Cambridge, MA (US);
Olivier Leger, Saint-Sixt, FR;
Qi An, Nashua, NH (US);
Mark Cartwright, West Newton, MA (US);
Sean D. McKenna, Duxbury, MA (US);
Vanita D. Sood, Somerville, MA (US);
Gang Hao, Belmont, MA (US);
Assignee:
Merck Patent GmbH, Darmstadt, DE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 45/06 (2006.01); A61K 31/555 (2006.01); A61K 39/395 (2006.01); A61K 31/675 (2006.01); A61K 31/7068 (2006.01); A61K 31/282 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 31/282 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/675 (2013.01); A61K 31/7068 (2013.01); A61K 39/0011 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61K 39/39591 (2013.01); A61K 45/06 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/73 (2013.01); C07K 2317/732 (2013.01); C07K 2317/92 (2013.01);
Abstract
The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and cancer.